DURHAM, NC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)GLIOBLASTOMA FOUNDATION INC, founded in 2016, is a community nonprofit in the Medical Research sector that reported $2.1M in total revenue in fiscal year 2024. Revenue surged 21% from the prior year, signaling strong growth momentum. Expenses of $1.8M left a modest 11% surplus.
THE GLIOBLASTOMA FOUNDATION IS DEDICATED TO FINDING A CURE FOR GLIOBLASTOMA BY FUNDING RESEARCH AND DRUG DEVELOPMENT, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS DEVASTATING BRAIN CANCER. THROUGH THESE INTEGRATED PROGRAMS, THE FOUNDATION ACCELERATES SCIENTIFIC DISCOVERY, EMPOWERS PATIENTS WITH INFORMATION AND RESOURCES, AND EDUCATES THE PUBLIC ABOUT THE URGENT NEED FOR BETTER TREATMENTS AND IMPROVED OUTCOMES.
RESEARCH AND DRUG DEVELOPMENT:IN 2024, THE GLIOBLASTOMA FOUNDATION ADVANCED ITS RESEARCH MISSION BY ACQUIRING LISAVANBULIN, A PROMISING TARGETED THERAPY FROM BASILEA PHARMACEUTICA, FOR FURTHER...
RESEARCH AND DRUG DEVELOPMENT:IN 2024, THE GLIOBLASTOMA FOUNDATION ADVANCED ITS RESEARCH MISSION BY ACQUIRING LISAVANBULIN, A PROMISING TARGETED THERAPY FROM BASILEA PHARMACEUTICA, FOR FURTHER CLINICAL DEVELOPMENT IN GLIOBLASTOMA. THIS ACQUISITION MARKED A CRITICAL STEP TOWARD BRINGING PATIENTS NEW, MORE EFFECTIVE TREATMENTS. THE FOUNDATION ALSO SUPPORTED INVESTIGATOR-INITIATED RESEARCH ON MOLECULAR CHARACTERIZATION AND FUNCTIONAL PRECISION ONCOLOGY. ADDITIONALLY, THE FOUNDATION ESTABLISHED GLIOLAB, A CLIA-REGISTERED GENOMIC LABORATORY THAT WILL PROVIDE STATE-OF-THE-ART TESTING TO ACCELERATE DISCOVERY OF TARGETED THERAPIES BASED ON EACH TUMOR'S GENOMIC AND EPIGENOMIC PROFILE.
PATIENT SUPPORT AND EDUCATION:THROUGHOUT 2024, THE FOUNDATION PROVIDED SUPPORT SERVICES FOR GLIOBLASTOMA PATIENTS AND CAREGIVERS NATIONWIDE, INCLUDING PERSONALIZED CLINICAL-TRIAL MATCHING...
PATIENT SUPPORT AND EDUCATION:THROUGHOUT 2024, THE FOUNDATION PROVIDED SUPPORT SERVICES FOR GLIOBLASTOMA PATIENTS AND CAREGIVERS NATIONWIDE, INCLUDING PERSONALIZED CLINICAL-TRIAL MATCHING, PROFESSIONALLY LED VIRTUAL SUPPORT GROUPS, AND EDUCATIONAL RESOURCES ON TREATMENT OPTIONS AND EMERGING RESEARCH. THESE PROGRAMS EMPOWERED PATIENTS TO MAKE INFORMED CARE DECISIONS AND FOSTERED A SENSE OF COMMUNITY AMONG FAMILIES AFFECTED BY THIS RARE DISEASE. HUNDREDS OF PATIENTS AND CAREGIVERS BENEFITED FROM THESE FREE SERVICES DURING THE YEAR.
PUBLIC AWARENESS AND ADVOCACY:THE FOUNDATION LED NATIONWIDE EFFORTS TO RAISE AWARENESS AND ADVOCACY FOR THOSE AFFECTED BY GLIOBLASTOMA. IN 2024, IT ORGANIZED GLIOBLASTOMA AWARENESS DAY AND CONTINUED...
PUBLIC AWARENESS AND ADVOCACY:THE FOUNDATION LED NATIONWIDE EFFORTS TO RAISE AWARENESS AND ADVOCACY FOR THOSE AFFECTED BY GLIOBLASTOMA. IN 2024, IT ORGANIZED GLIOBLASTOMA AWARENESS DAY AND CONTINUED THE VOICES OF GLIOBLASTOMA PODCAST WHILE PLANNING TO EXPAND THE SERIES IN FUTURE YEARS TO FEATURE ADDITIONAL PATIENT, CAREGIVER, AND SCIENTIST PERSPECTIVES. THE FOUNDATION ALSO PARTNERED WITH EVENTS SUCH AS THE LOS ANGELES MARATHON TO INCREASE PUBLIC UNDERSTANDING AND SUPPORT FOR RESEARCH. THESE INITIATIVES EDUCATED THOUSANDS AND INSPIRED HOPE WITHIN THE GLIOBLASTOMA COMMUNITY.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $2,055,218 | $1,699,784 | +0.2% |
| Expenses | $1,833,664 | $1,411,492 | +0.3% |
| Net Income | $221,554 | $288,292 | -0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| NEELAM KWATRA | PRESIDENT | 20.00 |
Officer
Director
|
$0 | $0 | $0 |
| MADAN KWATRA | TREASURER/SECRETARY | 4.00 |
Officer
Director
|
$0 | $0 | $0 |
| GITA KWATRA | CEO | 40.00 |
Officer
Director
|
$291,500 | $51,548 | $343,048 |
| CAMERON WEST | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| BRIAN AUSTIN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $2,055,218 | $1,833,664 | $3,662,658 | $221,554 |
| 2023 | $1,699,784 | $1,411,492 | $2,482,026 | $288,292 |
| 2022 | $1,471,550 | $853,578 | $1,781,399 | $617,972 |
| 2021 | $1,253,574 | $703,351 | $1,523,936 | $550,223 |
| 2020 | $958,672 | $323,928 | $1,140,681 | $634,744 |
| 2019 | $448,677 | $296,591 | $455,940 | $152,086 |
Compare GLIOBLASTOMA FOUNDATION INC with other nonprofits in North Carolina and across the country.